黛力新联合替普瑞酮对慢性胃炎患者临床疗效及焦虑抑郁情绪影响.docVIP

黛力新联合替普瑞酮对慢性胃炎患者临床疗效及焦虑抑郁情绪影响 　　[摘要] 目的 研究黛力新联合替普瑞酮对慢性胃炎患者临床疗效及其焦虑抑郁情绪的影响。 方法 选取我院2014年7月～2016年6月间收治的慢性胃炎患者136例，采用随机数字法将其分为对照组和观察组，每组各68例，对照组患者采用替普瑞酮治疗，观察组采用黛力新联合替普瑞酮治疗。比较两组患者临床疗效及治疗后不良反应情况，同时比较治疗前后两组患者汉密尔顿抑郁量表（HAMD）评分及汉密尔顿焦虑量表（HAMA）评分。结果 治疗后，观察组患者HAMD评分及HAMA评分均明显低于对照组（t=-2.258、-3.029，P0.05）。 结论 黛力新联合替普瑞酮治疗慢性胃炎患者，可以明显缓解患者焦虑抑郁情绪，提高临床治疗效果，改善患者生活质量，同时治疗后不良反应较少，值得在临床推广应用。 　　[关键词] 黛力新；慢性胃炎；HAMA评分；焦虑抑郁情绪 　　[中图分类号] R573.3 [文献标识码] B [文章编号] 1673-9701（2018）02-0092-04 　　[Abstract] Objective To study the effect of Deanxit combined with teprenone on the clinical efficacy and anxiety and depression in the patients with chronic gastritis. Methods 136 patients with chronic gastritis who were admitted to our hospital from July 2014 to June 2016 were selected as the study subjects. Random number method was used to divide them into control group and observation group， with 68 cases in each group. The control group was given teprenone， and the observation group was given Deanxit combined with teprenone. The clinical efficacy and adverse reactions of the two groups were compared. The Hamilton Depression Rating Scale（HAMD） scores and Hamilton Anxiety Scale （HAMA） scores were compared between the two groups before and after treatment. Results After treatment， HAMD scores and HAMA scores in the observation group were significantly lower than those in the control group （t=-2.258， -3.029， P0.05）. Conclusion Deanxit combined with teprenone in the patients with chronic gastritis can significantly relieve the anxiety and depression in patients， improve clinical efficacy， improve quality of life， while the adverse reactions are fewer after treatment， which is worthy of clinical promotion and application. 　　[Key words] Deanxit； Chronic gastritis； HAMA scores； Anxiety and depression 　　慢性胃???是临床较为常见的消化系统疾病，其发病机制主要是由多种病因共同作用，导致消化系统中胃黏膜出现慢性炎性反应[1，2]，临床表现为食欲减退、反酸及上腹隐痛等多种症状，严重影响患者正常生活质量[3]。流行病学研究显示[4]，我国60%以上人群患有慢性胃炎，其中中老年人由于各项机体功能退化，是该病的高发人群，随着现在生活压力日益加剧及饮食结构改变，该病发病率呈现年轻化趋势，受到人们广泛关注。该病早期症状不明显，容